Back to Search
JUAN FRIDMAN, MD
MD
Colon & Rectal Surgery Physician
NPI: 1831252428Individual
Specialties, Licenses & Credentials
Colon & Rectal Surgery PhysicianPrimary
Colon & Rectal Surgery
Code: 208C00000X
ME 27398(FL)
Research & Publications (20)
Education and advice contribute to increased density of broadleaved conservation trees, but not saplings, in young forest in Sweden.
PMID 18514381·J Environ Manage·2009
8-other
Compelling P1 substituent affect on metalloprotease binding profile enables the design of a novel cyclohexyl core scaffold with excellent MMP selectivity and HER-2 sheddase inhibition.
PMID 19457660·Bioorg Med Chem Lett·2009
8-other
Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo.
PMID 19139110·Mol Cancer Ther·2009
7-preclinical
Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model.
PMID 19507862·J Med Chem·2009
7-preclinical
Conversion of an MMP-potent scaffold to an MMP-selective HER-2 sheddase inhibitor via scaffold hybridization and subtle P1' permutations.
PMID 18068976·Bioorg Med Chem Lett·2008
8-other
Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor.
PMID 18757423·Cancer Res·2008
7-preclinical
Design and identification of selective HER-2 sheddase inhibitors via P1' manipulation and unconventional P2' perturbations to induce a molecular metamorphosis.
PMID 18036818·Bioorg Med Chem Lett·2008
8-other
Overweight more prevalent among children than among adolescents.
PMID 17391474·Acta Paediatr·2007
4-observational
Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer.
PMID 17363546·Clin Cancer Res·2007
7-preclinical
Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancer.
PMID 17256836·J Med Chem·2007
7-preclinical
Loss of p53 impedes the antileukemic response to BCR-ABL inhibition.
PMID 16651519·Proc Natl Acad Sci U S A·2006
7-preclinical
Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer.
PMID 16843264·Cancer Cell·2006
7-preclinical
Selective inhibition of ADAM metalloproteases blocks HER-2 extracellular domain (ECD) cleavage and potentiates the anti-tumor effects of trastuzumab.
PMID 16627988·Cancer Biol Ther·2006
7-preclinical
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy.
PMID 15029198·Nature·2004
7-preclinical
Tumor promotion by Mdm2 splice variants unable to bind p53.
PMID 14522887·Cancer Res·2003
7-preclinical
An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo.
PMID 12567186·Nat Genet·2003
7-preclinical
An assessment of the potential for reducing future combat deaths through medical technologies and training.
PMID 12478044·J Trauma·2002
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 8900 N KENDALL DR, DEPARTMENT OF MEDICAL EDUCATION
MIAMI, FL 33176 - Phone
- (786) 596-7232
Quick Facts
- NPI
- 1831252428
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile